10011247  CAY10574

(CAS 140651-18-9)




For active pharmaceutical ingredients (APIs) related to CAY10574, see Cayman Pharma

Cyclin-dependent kinases (CDKs) play a key role in regulating cell division by phosphorylating distinct substrates in different phases of the cell cycle. Cell cycle deregulation in many cancers often results from altered CDK activity. Thus, CDKs are potential pharmacological targets for anticancer agents. CAY10574 is a potent, selective inhibitor of CDK9 in vitro with an IC50 value of 0.35 µM. It is also a competitive inhibitor of CDK2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively.1 CAY10574 reduces the population of S-phase cells of the cancer cell line HT-29 and blocks proliferation of several other cancer cell lines including MCF7, HOS, G361, and K562 cells with IC50 values of 33, 49, 64, and 62 µM, respectively.1
1  Krystof, V., Cankar, P., Frysová, I., et al. 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 49 6500-6509 (2006).

Download Product Insert 127 Kb PDF

Pricing Information

Prices listed here are the Manufacturer's Suggested European Retail Price. The actual prices quoted by each individual distributor may vary. Please visit the Global Buyer's Guide on the Cayman Chemical (world) website to locate a distributor in your region.

This product is also available to buy in bulk quantities. Please contact us for a quote or to purchase.

Cayman strives to be a reliable biochemical reagent vendor by providing the best possible products and services. To ask for assistance with one of our products please contact our Technical Help staff.

Warning This product is not for human or veterinary use.

Item total €0.00
Shopping cart total €0.00
Size Price Quantity
1 mg €22.00
5 mg €98.00
10 mg €173.00
50 mg €756.00
Pricing updated 2010-09-09.
Prices are subject to change without notice.